Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
E: investor-relations@haleon.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.70 | 43.70 | 0.52% |
| CAC 40 | 7,863.03 | 12.93 | 0.16% |
| DAX 40 | 23,613.04 | 46.50 | 0.20% |
| Dow JONES (US) | 42,242.08 | 168.02 | -0.40% |
| FTSE 100 | 8,602.07 | 2.91 | -0.03% |
| HKSE | 23,108.27 | 441.19 | -1.87% |
| NASDAQ | 18,996.77 | 288.42 | 1.54% |
| Nikkei 225 | 38,183.26 | 539.00 | 1.43% |
| NZX 50 Index | 12,786.74 | 109.99 | 0.87% |
| S&P 500 | 5,890.86 | 46.67 | 0.80% |
| S&P/ASX 200 | 8,269.00 | 35.50 | 0.43% |
| SSE Composite Index | 3,374.87 | 5.63 | 0.17% |